Monthly Archives: July 2026

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

10/07/2026 – AB Science today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for AML and the masitinib program for ALS

AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development

08/07/2026 – Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer

AB Science announces the successful completion of a EUR 2.3 million private placement

01/07/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors